INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Review Article

Review on Co-Crystallization for Solubility Enhancement

Mohiuddin Shaikh, Shaikh Taufique Akil*, Shaikh Aawez, Alaisa Khan, Aadil Ahmad, Umair Ali Khan, MD Rashid

Vastanvi College Of Pharmacy, Kannad, Aurangabad, Maharashtra, India - 431103.

ARTICLE INFO

Published: 30 June 2025
Keywords:
Co-Crystallization, Solubility, Bioavailability, Pharmaceutical Cocrystals, BCS Classification, Drug Delivery
DOI:
10.5281/zenodo.15771618

ABSTRACT

Co-crystallization is a promising strategy in pharmaceutical formulation for improving the solubility, stability, and bioavailability of poorly water-soluble drugs. This review explores the mechanisms, advantages, and practical methodologies of co-crystallization, highlighting recent advances in the field. Co-crystals, composed of active pharmaceutical ingredients (APIs) and conformers linked by non-covalent interactions, present a viable alternative to traditional approaches such as salt formation and amorphization. This article summarizes the Biopharmaceutical Classification System (BCS) relevance, applications, advantages, limitations, and evaluation methods of co-crystals, with a comprehensive literature survey and discussion on various formation techniques.

INTRODUCTION

Solid oral dosage forms such as tablets and capsules are the most common means of drug delivery. However, many active pharmaceutical ingredients (APIs) cannot be formulated in their pure form due to instability or poor solubility. Co-crystallization has emerged as a powerful technique to overcome these challenges, enhancing the physicochemical properties of APIs without altering their pharmacological profile. Co-crystals are crystalline materials composed of an API and a neutral coformer, held together through non-covalent interactions such as hydrogen bonding. They differ from other solid forms like salts, polymorphs, and solvates in that they do not require ionizable groups. This approach is particularly useful for BCS Class II and IV drugs, which suffer from poor water solubility and limited bioavailability.

2. Need and Objective

Many newly developed drugs exhibit poor aqueous solubility, limiting their therapeutic potential. Co-crystallization addresses this by

***Corresponding Author:** Shaikh Taufique Akil
Address: *Vastanvi College of Pharmacy, Kannad, Aurangabad, Maharashtra, India - 431103.*
Email ✉: tofik55gnagar@gmail.com
Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

enhancing the solubility and dissolution rate without chemical modification. This makes it a valuable tool in drug development, especially for non-ionizable drugs. The primary objective of co-crystallization is to create multicomponent systems that improve drug properties such as solubility, stability, mechanical strength, and bioavailability. By employing pharmaceutical coformers, a wide range of APIs can be improved through crystal engineering techniques.

According to the Biopharmaceutical Classification System (BCS), drugs are categorized into four classes based on their solubility and permeability. Co-crystallization offers a targeted strategy to enhance the solubility of drugs in Classes II and IV. Examples include co-crystals of ibuprofen with nicotinamide (BCS Class II), and furosemide with caffeine (BCS Class IV), which have demonstrated improved dissolution and bioavailability.

3. BCS Classification and Examples

Class 1	High solubility/ high permeability	B- blockers propanol
Class 2	Low Solubility / High Permeability	NSAIDS Ketoprofen , Antiepileptic , Carbazepine , Phenytoin, Nifedepine
Class 3	High Solubility / Low permeability	B blockers Atenolol , H2 antiagonist Ranitidine
Class 4	Low solubility / Low permeability	Diuretics Hydroclorthiazide , Frusemide , Taxol

Defination	Parts Of Solvent Required For 1 Part Of Solute
Very Soluble	Less Than 1
Freely Soluble	From1-10
Soluble	From 10-30
Sparingly Soluble	From30-100
Slightly Soluble	From 100-1000
Very Slightly Soluble	From 1000-10000
Insoluble	Greater Than 10000

4. Applications of Co-crystallization

Co-crystals improve various drug properties including:

- Bioavailability: Enhanced solubility leads to increased absorption.

- Dissolution: Intrinsic dissolution rate is improved without altering the drug chemically.

- Stability: Both physical and chemical stability of the drug is maintained.

- Mechanical Properties: Better compressibility and flow make them suitable for tablet formulation.

- Sustained Release and Therapeutic Effect: Modified release profiles and improved therapeutic outcomes are achievable.



5. Advantages and Limitations

Pharmaceutical co-crystallization presents several advantages:

- Can be applied to APIs without ionizable functional groups.

- Uses a broad range of pharmaceutically acceptable coformers.

- Enhances solubility, stability, mechanical strength, and tabletability.

- Solvent-drop grinding and other green methods reduce solvent use.

- Allows purification and formulation flexibility without altering pharmacological activity.

However, co-crystallization also has certain limitations:

- Lack of a complete understanding of co-crystal formation and structure-property relationships.

- Stability concerns under varying temperature and humidity.

- Challenges in separation and identification due to small particle size in grinding methods.

- Possible phase transitions during storage or processing.

6. Methods of Co-crystallization

Various methods are employed in co-crystal formation:

- Grinding Method (Dry and Liquid-Assisted): Simple, cost-effective, and environmentally friendly.

- Slurry Method: Involves suspension of API and coformer in solvent and stirring.

- Antisolvent Addition: Addition of miscible solvent to induce co-crystal precipitation.

- Hot Melt Extrusion: Solvent-free, continuous process involving heat and mixing.

- Spray Drying: Dissolution followed by rapid evaporation to yield fine co-crystals.

- Supercritical Fluid Technique: Uses CO2 under pressure for crystallization.

- Sonocrystallization: Ultrasonication promotes nucleation and crystallization.







7. Characterization Techniques

Co-crystals are characterized using various techniques to assess their properties:

- Solubility Testing: Measures improvements over pure API.

- Stability Studies: Assesses humidity and thermal stability.

- Melting Point Determination: Indicates successful co-crystal formation.

- Tabletability: Evaluates compression and flow properties.

- Permeability: Log P-based assessment using in vitro models.

- Bioavailability: In vivo and in vitro studies compare drug release from co-crystals vs. pure drugs.





8. RESULTS

Co-crystallization significantly enhances the physicochemical performance of poorly water-soluble APIs. Experimental and literature evidence shows that solubility, dissolution rate, stability, and tabletability are all improved using suitable coformers and optimized methods.

9. CONCLUSION

Co-crystallization offers a robust and flexible approach for improving drug delivery, particularly for BCS Class II and IV drugs. It bypasses the need for ionizable groups, allows the use of diverse coformers, and integrates well with existing pharmaceutical processes. With increasing interest in crystal engineering, co-crystals are poised to become a standard in formulation development.

REFERENCES

1. Altaf AN and Yasser A: Pharmaceutical co-crystals: A new paradigm of crystal engineering. Journal of Indian Institute of Science 2014; 94: 45-68.
2. Ainurofiq A (2021). A review on solubility enhancement methods for poorly water-soluble drugs. J Rep Pharm Sci, Vol. 10, No: 137-47.
3. Almarsson, Ö., & Zaworotko, M. J. (2004). Crystal engineering of the composition of pharmaceutical phases: new approaches to the design of multi-component crystalline solids. Chemical Communications, (17), 1889–1896.
4. 4)Mohammad MA, Alhalaweh A, Velaga SP. Hansen solubility parameter as a tool to predict cocrystal formation. International Journal of Pharmaceutics,2011:407(1-2):63-71.
5. Karimi-Jafari M, Padrela L, Walker GM, Croker DM. Creating cocrystals: a review of pharmaceutical cocrystal preparation routes and applications. Crystal Growth & Design,2018:18(10):6370-6387.
6. Vogt FG, Clawson JS, Strohmeier M, Edwards AJ, Pham TN, Watson SA. Solid-state NMR analysis of organic cocrystals and complexes. Crystal Growth & Design,2009:9(2):921-937.
7. Zhao L, Hanrahan MP, Chakravarty P, DiPasquale AG, Sirois LE, Nagapudi K, et al. Characterization of pharmaceutical cocrystals and salts by dynamic nuclear polarization enhanced solid-state NMR spectroscopy. Crystal Growth & Design,2018:18(4):2588-2601.
8. Guo C, Zhang Q, Zhu B, Zhang Z, Ma X, Dai W, Gong X, Ren G, Mei X. Drug–drug cocrystals provide significant improvements of drug properties in treatment with progesterone. Crystal Growth & Design,2020:20(5):3053-3063.
9. Maheshwari C, JayasankMacFhionnghaile P, Crowley CM, McArdle P, Erxleben A. Spontaneous solid-state cocrystallization of caffeine and urea. Crystal Growth & Design,2020:20(2):736-745.ar A, Khan NA, Amidon GE, Rodríguez-Hornedo N. Factors that influence the spontaneous formation of pharmaceutical cocrystals by simply mixing solid reactants. CrystEngComm,2009:11(3):493-500.
10. Savjani, J.K., 2015. Co-crystallization: an approach to improve the performance characteristics of active pharmaceutical ingredients. Asian Journal of Pharmaceutics (AJP): Free full text articles from Asian J Pharm, 9(3), pp.147-151
11. Thakuria R (2018). Drug-drug and drug-nutraceutical co-crystal/salt as alternative medicine for combination therapy: a crystal engineering approach. Crystals, Vol.8, No:101
12. Varun Raj Vemula (2010). Solubility Enhancement Tecniques. International Journal of Pharmaceuticals Sciences Review and Research, Vol. 5, No: 41-51
13. Sheetal Z Godsel (2013). Phytochemical and Pharmacological Profile of lanata camara L.: An Overview. J. Adv. Pharm. Edu. & Res, Vol. 3, No: 403-414
14. Aakeröy CB, Fasulo M, Schultheiss N, Desper J, Moore C. Structural competition between hydrogen bonds and halogen bonds. J Am Chem Soc,2007:129:13772-13773.
15. Desiraju GR. Supramolecular synthons in crystal engineering a new organic synthesis.

Angew Chem Int Ed Engl. 1995:34:2311-2327.

16. Bysouth SR, Bis JA, Igo D. Cocrystallization via planetary milling: enhancing throughput of solid-state screening methods. International Journal of Pharmaceutics,2011:411:169-171.
17. Wu TK, Lin SY, Lin HL, Huang YT. Simultaneous DSC-FTIR micro spectroscopy used to screen and detect the co-crystal formation in real time. Bioorganic & Medicinal Chemistry Letters,2011:21:3148-3151.
18. Raza SA, Schacht U, Svoboda V, Edwards DP, Florence AJ, Pulham CR, et al. Rapid continuous antisolvent crystallization of multicomponent systems. Cryst Growth Des,2018:18(1):210-218.!
19. Yadav BK, Khursheed A, Singh RD. Co-crystals: a complete review on conventional and novel methods of its formation and its evaluation. Published by Innovare Academic Sciences Pvt. Ltd,2019:12(7): 68-74.
20. Kumar S, Nanda A. Pharmaceutical cocrystals: an overview. Indian Journal of Pharmaceutical Sciences,2017:79(6):858-871.
21. Chaudhari S, Nikam S, Khatri N, Wakde S. Co-crystals: a review. Journal of Drug Delivery and Therapeutics,2018:8(6):350-358
22. Varun Raj vemula (2010),solubility enhncment Techniques . International Journal of pharmaceuticals sciences Review .Ars
23. Sekhon BS: Pharmaceutical co-crystals-a review. Ars Pharm 2009; 50(3): 99-17.
24. Upadhyay N, Shukla TP, Mathur A, Manmohan and Jha SK: Pharmaceutical co-crystal: an emerging approach to improve physical property. International Journal of Pharmaceutical Sciences Review and Research 2011; 8(1):144-48.
25. Veerendra KN, Manvi FV and Shamrez AM: New trends in the co-crystallization of active pharmaceutical ingredients. Journal of Applied Pharmaceutical Science 2011; 1(8): 1-5.
26. Zalte S (2020). Pharmaceutical Co-Crystallization- A novel trend in solubility enhancement of API. World Journal Of Pharmacy And Pharmaceutical Sciences, Vol. 9, No: 511-525.
27. Patel D (2020). Pharmaceutical Co-crystal : An emerging technique to enhance Physicochemical properties of drugs. International Journal of Chem Tech Research, Vol. 13, No: 283-309.
28. Shalu Shukla (2020). A review on solubility enhancement techniques. Ijppr.Human, Vol. 19, No: 312-328.

HOW TO CITE: Mohiuddin Shaikh, Shaikh Taufique Akil*, Shaikh Aawez, Alaisa Khan, Aadil Ahmad, Umair Ali Khan, MD Rashid, Review on Co-crystallization for Solubility Enhancement, Int. J. of Pharm. Sci., 2025, Vol 3, Issue 6, 5816-5823. https://doi.org/10.5281/zenodo.15771618